| Literature DB >> 35821887 |
Song Lin1, Xiaoshan Li2, Yan Zhang3, Xiaowen Mao1, Xingchi Liang1, Shigang Cheng1, Lingli Zhang4.
Abstract
Methods: We grouped the patients who had undergone cervical cancer surgery in a hospital in this article and compared the nanodrug carrier system under CT imaging with traditional laparoscopy. The postoperative physical parameters of surgical patients are collected from cervical cancer patients of different degrees, and the parameters and prognostic health of patients after different operations are compared.Entities:
Mesh:
Year: 2022 PMID: 35821887 PMCID: PMC9217568 DOI: 10.1155/2022/2572681
Source DB: PubMed Journal: Contrast Media Mol Imaging ISSN: 1555-4309 Impact factor: 3.009
Figure 1Schematic diagram of the drug delivery system.
Cervical cancer staging.
| FIGO staging | Tumor area |
|---|---|
| I | Stage I tumors are limited to the uterus |
| I A | Invasive cervical cancer diagnosed under microscope |
| II | The tumor exceeds the cervix and does not reach the pelvic wall |
| II A | Tumor does not invade parauterine tissues |
| III | The tumor reaches the pelvic wall or 1/3 of the vagina |
| III A | The tumor invaded the lower 1/3 of the vagina without invading the pelvic wall |
| IV | Tumor invades the bladder or rectal mucosa |
| IV A | Tumor dissemination value adjacent organs |
| IV B | Distant metastasis of tumor |
Figure 2The treatment process.
Figure 3Image denoising effect.
General clinical data of patients.
| Nano-drug-loaded surgery group | Laparoscopic surgery group |
|
| |
|---|---|---|---|---|
| Total number (cases) | 368 | 124 | — | — |
| Age | 45.78 ± 8.72 | 45.82 ± 8.02 | −0.045 | 0.954 |
| BMI | 21.63 ± 3.91 | 20.82 ± 3.17 | 2.301 | 0.021 |
| Staging (example) | — | — | 3.486 | 0.511 |
| I | 32 | 2 | — | — |
| I a | 205 | 78 | — | — |
| II | 98 | 22 | — | — |
| II a | 34 | 22 | — | — |
The number of people with different pathological types.
| Pathological type | Nano-drug-loaded surgery group | Laparoscopic surgery group |
|
|
|---|---|---|---|---|
| Squamous cell carcinoma | 323 | 111 | — | — |
| Adenocarcinoma | 25 | 8 | — | — |
| Other | 10 | 6 | — | — |
| History of pelvic and abdominal surgery | 181 | 56 | 0.752 | 0.373 |
Postoperative conditions of patients.
| Nano-drug-loaded surgery group | Laparoscopic surgery group |
|
| |
|---|---|---|---|---|
| Operation time (min) | 184 | 169 | 5.049 | <0.001 |
| Intraoperative blood loss (ML) | 50 | 100 | −5.114 | <0.001 |
| Intraoperative blood transfusion | 0 | 1 | 0.313 | 0.569 |
| Conversion to laparotomy | 0 | 1 | 0.313 | 0.569 |
| Exhaust time (d) | 1.29 ± 0.21 | 1.42 ± 0.22 | −1.554 | 0.043 |
| Maximum body temperature (°C) | 14 | 20 | −4.123 | <0.001 |
| Maximum body temperature (°C) | 37.5 | 37.6 | −1.780 | 0.049 |
| Length of stay (d) | 6 | 6 | −2.693 | 0.007 |
| Number of lymph node dissections | 18 | 18 | 0.368 | 0.605 |
Figure 4Postoperative complications.
Figure 5Postoperative pathology.
Figure 6Follow-up of patients.
Figure 7Postoperative quality of life.
Figure 8Daily life survey of patients.
Figure 9Pathological results between groups.